Day: January 31, 2024
NORCROSS, Ga., Jan. 31, 2024 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, intends to hold an investor conference call on February 14, 2024, at 11:00 A.M. Eastern Time in conjunction with the company’s earnings release for the quarter ended December 31, 2023. The company plans to issue a press release with the financial results for the period before the market opens on February 14, 2024.
Interested investors are invited to attend the conference call by accessing the webcast at https://www.webcast-eqs.com/register/corecard02142024/en or by dialing 1-877-407-0890. As part of the conference call CoreCard will be conducting a question-and-answer session where participants are invited to email...
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Written by Customer Service on . Posted in Public Companies.
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is...
Pharmaceutical Analytical Testing Outsourcing Market Set to Soar Past USD 15.09 Billion by 2030
Written by Customer Service on . Posted in Mergers And Acquisitions.
The global Pharmaceutical Analytical Testing Outsourcing market size is expected to reach USD 15.09 billion by 2030 and exhibit a CAGR of 8.4% in the forecast period (2023−2030), according to Skyquest’s latest research report. The pharmaceutical industry pressures, cost reduction, increased regulatory demands, specialized expertise, technological advancements, global expansion, time-to-market constraints, risk mitigation, capacity constraints, resource optimization, focus on core competencies, and outsourcing partners is fueling the market’s growth.
Westford USA, Jan. 31, 2024 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Pharmaceutical Analytical Testing Outsourcing market, emerging markets, increasing complex biologics, personalized medicine, data analytics and AI adoption, virtual...
Meso Numismatics Increases 2023 Sales By 50% Year Over Year and Announces 2024 Forecast and Outlook
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
LAS VEGAS, NV , Jan. 31, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company, is pleased to announce that it closed its 2023 fiscal year with approximately $2.4 million in sales, a more than 50% increase over 2022 levels. Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures. The Company expects to reach $5 million in revenues with approximately $1 million in operating profits (defined as gross profit less total operating expenses) for its fiscal year 2024. Although overall sales are expected to increase, the significant sales increase is expected to come from the patient procedure category as the Company’s Cancun based clinic starts to increase the total number of monthly patient procedures.
The...
Trinity Biotech Announces Q3 2023 Financial Results & Business Update
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
-Investor call to be held today at 8:30 am EST
DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
Business Updates and Strategic Priorities
In December 2023, the Company announced the promotion of John Gillard from CFO to CEO and the promotion of Des Fitzgerald to the role of Interim CFO. The new management team has now put in place a clear set of strategies and priorities as set out below.
Biosensor technology acquisitionThe Company has today announced the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) for $12.5 million in cash and 9 million American Depositary Shares (“ADS”) plus contingent consideration.
Driven by this transaction, the Company intends to use its newly acquired...
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
Written by Customer Service on . Posted in Public Companies.
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:Date:
Wednesday,...
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Written by Customer Service on . Posted in Public Companies.
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.
A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed...
AirSculpt Technologies Announces Fourth Quarter 2023 Earnings Release Date and Conference Call
Written by Customer Service on . Posted in Public Companies.
MIAMI BEACH, Fla., Jan. 31, 2024 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report fourth quarter 2023 financial results before market open on Tuesday, February 27, 2024, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.
The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13743630 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.elitebodysculpture.com. A replay of the webcast will be available for approximately 90 days.
About AirSculpt
AirSculpt®...
Arqit awarded ISO 27001 Certification for Information Security Management
Written by Customer Service on . Posted in Public Companies.
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, has received ISO/IEC 27001 certification for information security and cybersecurity protection.
Recognised as the world’s best-known standard for data security, ISO/IEC 27001 conformity demonstrates Arqit’s commitment to securing data and with our groundbreaking Symmetric Key Agreement Platform, offering customers a standards-compliant, easily integrated solution to harden networks against current and future cyber threats including from quantum computers.
The 2024 Global Risks report from the World Economic Forum highlighted that enterprises and other organisations place cyber insecurity in their top ten risks over both the short and long term. Legacy encryption is obsolete and urgent action is required...
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Written by Customer Service on . Posted in Public Companies.
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 11:30 AM EST.
A live webcast of the presentation will be available under the “Events & Presentations” tab on the “Investors” page on the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology...